ATLANTA, GA--(Marketwire - May 05, 2008) - MIV Therapeutics, Inc. (OTCBB: MIVT) (FRANKFURT: MIV) (“the Company”), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, today announced that its VESTAsync™ polymer-free nanoscale microporous hydroxyapatite drug-eluting stent will be included in several presentations at EuroPCR08 in Barcelona. EuroPCR is the official congress of the European Association for Percutaneous Cardiovascular Interventions. The congress is being held from May 13th to 16th.
